Disclosed is the use of nanoparticles comprising rapamycin and a carrier protein for the manufacture of a medicament for the treatment of a proliferative disease in an individual. Also disclosed is the use of nanoparticles comprising a taxane and a carrier protein for the manufacture of a medicament for the treatment of a proliferative disease in an individual, wherein the medicament is formulated to provide a weekly dose of 100 to 150 milligrams per square meter of body surface, or 0.25 percent to 25 percent of its maximum tolerated dose following a traditional dosing regime.
